Clinical Trials in Georgia

Showing 5781-5800 of 19,050 trials

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

NCT04980872

This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS). This is an extension of other miransertib studies (MK-7075-002 \[NCT03094832\] or ArQule CU/EAP \[NCT03317366\]), and may also enroll participants who are approved for MK-7075-002 but have not yet started miransertib therapy.

Merck Sharp & Dohme LLC60 participantsStarted Nov 2021

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Cincinnati, Ohio, United States +8 more locations

Active Not RecruitingPhase 265 miles

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

NCT05032040

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

Ovarian CancerClear Cell CarcinomaEndometrial Cancer+2 more

Xencor, Inc.170 participantsStarted Jul 2022

Prescott, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +14 more locations

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Find Trials by Condition in Georgia

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Framing Eighteen Coils in Cerebral Aneurysms Trial

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Open-Label Study of Setmelanotide in Hypothalamic Obesity

A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

A Food Additive Removal Diet for Pediatric Eosinophilic Esophagitis

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

A Study of SGN-ALPV in Advanced Solid Tumors

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors